English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Following the publication of this article, an interested reader drew to our attention that, in Table IV, we describe a c.1081C>T, p.Arg361X mutation in collagen type I, alpha 2 (COL1A2). Codon 361 is a glycine residue, not an arginine, according to the transcript, Z74616.1. We re‑examined the original data, and identified that the mutation c.1081C>T, p.Arg361X was of the collagen type I, alpha 1 COL1A1 gene, and furthermore, it was not novel in the mutation spectrum of COL1A1. Therefore, in the paper, the c.1081C>T, p.Arg361X mutation should have appeared in Table III (not Table IV), which described the clinical and genetic characteristics of probands with mutations in COL1A1, with an indication in the final column of the Table that it was not novel in the mutation spectrum of COL1A1. This error did not affect the major conclusions drawn in this study. We sincerely apologize for this mistake, and thank the reader of our article who drew this matter to our attention. [the original article was published in the Molecular Medicine Reports 14: 4918‑4926, 2016; DOI: 10.3892/mmr.2016.5835].

Clinical characteristics and the identification of novel mutations of COL1A1 and COL1A2 in 61 Chinese patients with osteogenesis imperfecta